A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

Andrew M. Evens*, Steven T. Rosen, Irene Helenowski, Justin Kline, Annette Larsen, Jennifer Colvin, Jane N. Winter, Koen M. van Besien, Leo I. Gordon, Sonali M. Smith

*Corresponding author for this work

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

There remains an unmet therapeutic need for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL). We conducted a phase I/II trial with bortezomib (dose-escalated to 1·6 mg/m2) given concurrently with gemcitabine (800 mg/m2) days 1 + 8 q21 d. Of 32 patients, 16 each had relapsed/refractory PTCL and DLBCL. Median prior therapies were 3 and 35% had failed transplant. Among the first 18 patients, 67% experienced grade 3/4 neutropenia and/or grade 3/4 thrombocytopenia resulting in repeated treatment delays (relative dose intensity: 46%). Thus, the study was amended to give bortezomib and gemcitabine days 1 + 15 q28 d, which resulted in markedly improved tolerability. Among all patients, the overall response rate (ORR) was 24% with 19% complete remission (CR; intent-to-treat (ITT) ORR 16%, CR 13%), which met criteria for futility. The ORR for DLBCL was 10% (CR 10%) vs. 36% for PTCL (CR 27%). Among 6 PTCL patients treated on the modified schedule, ORR by ITT was 50% (CR 30%). Altogether, concurrent bortezomib/gemcitabine given days 1 + 8 q21 d was not tolerable, while modification to a bi-monthly schedule allowed consistent treatment delivery. Whereas efficacy of this combination was low in heavily pre-treated DLBCL, there was a signal of activity in relapsed/refractory PTCL utilizing the modified schedule.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalBritish Journal of Haematology
Volume163
Issue number1
DOIs
StatePublished - Oct 1 2013

    Fingerprint

Keywords

  • Bortezomib
  • Diffuse large B-cell lymphoma
  • Gemcitabine
  • Lymphoma
  • Peripheral T-cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this